Skip Navigation


Rheumatology Advance Access originally published online on November 28, 2006
Rheumatology 2007 46(4):561-562; doi:10.1093/rheumatology/kel398
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Rheumatology First Quarter 2007 Quiz
Right arrow All Versions of this Article:
46/4/561    most recent
kel398v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Armstrong, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, D. J.
Related Collections
Right arrow Osteoarthritis and Cartilage
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIALS

Celecoxib and CVS risk—lessons from the APC and PreSAP studies

D. J. Armstrong

Department of Rheumatology, University Hospital of North Durham, North Road, Durham

Correspondence to: D. J. Armstrong. E-mail: oswald17727@hotmail.com

The first 10% of the full text of this article appears below.

Since the return of Robin Goodfellow to the land of the faeries, we mortal rheumatologists have had to scan the general medical press ourselves for items of arthritic interest. One wonders what Robin might have made of the two large trials of celecoxib for the prevention of colonic adenomatous polyps recently published in the New England Journal of Medicine [1, 2], and of the generally negative view of the accompanying editorial [3] with respect to balancing risks and benefits. If coxibs are too dangerous to use to prevent pre-malignant polyps (he might have asked), can one safely assume they are too dangerous to prescribe for sore knees?

A total of over 3000 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?